EORTC-22996-24002-ROG-HNCG - 24002

A phase III double-blind, randomized, placebo-controlled study of Erythropoietin when used as an adjuvant to radiation therapy in patients with head and neck squamous cell carcinoma. EORTC 22996-24002
Trial StatusAll trial activities ended
DatesDate of activation: 12-Mar-01
Closed on : 04-Apr-03
Data management at EORTCFull
Phase3
Randomized trialYes
TypeAdjuvant
Targeted Sample size762
Number of steps1
DrugRecombinant human erythropoietin alfa
Study Staff
Type of cancerHead and Neck
Participating GroupsEORTC Radiation Oncology Group(Coordinating Group)
EORTC Head and Neck Cancer Group
Arbeitsgemeinschaft Radiologische Onkologie
Groupe d'Oncologie et Radiotherapie Tete et Cou
Radius Hungaricus Oncology Group
Trans-Tasman Radiation Oncology Group Inc
Protocol summaryCancer.gov (PDQ)
ClinicalTrials.gov
NCT numberNCT00017277
EudraCT